Glenmarks novel monoclonal antibody GBR 830 to enter Phase 2 clinical studies in Atopic Dermatitis and Celiac Disease in US and Europ
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated September 03, 2015 titled "Glenmarks novel monoclonal antibody GBR 830 to enter Phase 2 clinical studies in Atopic Dermatitis and Celiac Disease in US and Europe".03-09-2015